News
Did Eli Lilly Just Say Checkmate to Novo Nordisk?
Novo Nordisk (NYSE: NVO) has seen revenue soar in recent years thanks to two drugs that have helped people around the world lose weight. The molecule is semaglutide, and it's sold under the name Ozempic for type 2 diabetes and Wegovy for weight loss -- but doctors have prescribed either for weight management.
With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...
Novo Nordisk argues Medicare should negotiate the price for six of its insulin products separately, though they contain the ...
Guggenheim’s Seamus Fernandez cut his rating on Novo Nordisk stock to Hold from Buy on Thursday, as did Evan David Seigerman ...
The FDA has issued a warning about counterfeit Ozempic medications, sharing the lot numbers and serial numbers of products ...
A unique Novo Nordisk legal challenge to the Medicare drug pricing program could have big implications for the pharma ...
Novo Nordisk's stocks face YTD struggles due to trial results and tariffs, but strong fundamentals and outlook justify a Buy.
Danish drugmaker Novo Nordisk said on Monday several hundred counterfeit units of its diabetes drug Ozempic were being ...
U.S. regulators are trying to shut down the industry for compounded weight-loss drugs, which could result in higher costs or ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback